Amylyx Pharmaceuticals, Inc. (AMLX) Balance Sheet

The sequential decline in total assets is driven by cash depletion and the absence of revenue, reflecting the company's transition to a clinical-stage entity. Equity has also contracted from $324.4M to $239.2M over the same period, indicating that losses are eroding the capital base. This trajectory suggests the balance sheet is weakening, though the pace of decline has moderated as cost cuts take effect.

The sharp cash decline in 2026Q2 is alarming, though the current ratio of 12.12 suggests ample short-term assets to cover liabilities. However, with zero revenue and a quarterly operating burn of roughly $31M, the cash balance of $49.3M may only sustain operations for about 1.5 quarters, based on the latest cash flow data. This implies a high risk of needing to raise capital or pursue strategic alternatives before the next data readouts.

The company's debt load is minimal, providing financial flexibility and reducing refinancing risk. However, this also means the company cannot rely on debt markets to fund operations; it must depend on equity raises or partnerships. The low leverage is a positive, but it does not offset the urgent need for cash to fund ongoing clinical trials.

The absence of goodwill and minimal PPE underscores that AMLX's value lies in its intellectual property and clinical pipeline, not physical assets. This asset-light structure is typical for biotech, but it also means the balance sheet offers little collateral for borrowing. The decline in PPE from $5.7M in 2024Q1 to $4.7M suggests a scaling down of physical infrastructure, consistent with the wind-down of commercial operations.

The accumulated deficit has more than doubled over the period, indicating that the company has burned through substantial capital without generating returns. Despite this, equity remains positive at $239.2M due to prior capital raises, but the trend is concerning. The negative retained earnings highlight the lack of profitability and the reliance on external funding to sustain operations.